• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOSENSE WEBSTER INC UNK_SMART TOUCH UNIDIRECTIONAL SF; CARDIAC ABLATION PERCUTANEOUS CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOSENSE WEBSTER INC UNK_SMART TOUCH UNIDIRECTIONAL SF; CARDIAC ABLATION PERCUTANEOUS CATHETER Back to Search Results
Catalog Number UNK_SMART TOUCH UNIDIRECTIONAL
Device Problem Patient Device Interaction Problem (4001)
Patient Problem Pericardial Effusion (3271)
Event Date 01/01/2021
Event Type  Injury  
Manufacturer Narrative
Manufacturer's ref.No: (b)(4).Investigation summary: since the product has not been returned, no corrective action is warranted at this time.As a result, we are closing this investigation.If the complaint device is received in the future, we will reopen the complaint and perform the investigation as appropriate.Device history record (dhr) review cannot be conducted because the lot number was provided by the customer.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
 
Event Description
"this complaint is from a literature source.The following literature cite has been reviewed: mavilakandy a., sidhu b., man s., antoun i., vali z., de almeida t.P., li x., lazdam m., ibrahim m., chins., sandilands a., stafford p., somani r., ng a.A tertiary centre experience comparing new temperature-controlled high-power short duration ablation technology with standard radiofrequency and cryo-energy ablation.Heart.2021 jun; conference: british cardiovascular society annual conference, 'cardiology and the environment'.Virtual.107 (suppl 1) :a84-a85.Objective: pulmonary vein isolation (pvi) is an established treatment strategy for atrial fibrillation (af).Radiofrequency (rf) ablation technology has evolved over the last decade with the very high-power short-duration(vhpsd) temperature- controlled ablation approach emerging as the latest development.The purpose of this study was to determine the procedural efficacy, metrics and safety of vhpsd ablation with conventional power-controlled rf(pcrf) ablation and cryoenergy ablation (cryo).Methods/study data: a prospective single tertiary center analysis was performed on patients undergoing first time pvi ablation from 2019 to 2020.The population was divided in to 4treatment arms; qmode plus (vhpsd), qmode (qmode), pcrf using thermocool smarttouch sf catheter (stsf) and cryo.Demographics, clinical and procedural metrics such as pvi duration, ablation time and sedation requirement were collated.Patients were monitored for perioperative complications.Results one hundred patients underwent ablation with 25 cases conducted in each arm.Complete pvi was attained in all study subjects.No adverse procedural events were recorded for the vhpsd while 2 pericardial effusions occurred in the pcrf group, 1 cardiac tamponade in the qmode group and 2 transient ischemic attacks in the cryo group.Conclusion with the emergence of vhpsd rf ablation, preliminary findings indicate significant potential in reduction of procedural and ablation time.Further analysis is ongoing in order to ascertain longer-term efficacy and patient safety.The manufacturer of the device used to perform the cryo is unknown, and assumed to be a bwi thermocool product.Lot, model and catalog number are not available, but the suspected biosense device possibly associated with reported adverse events: q mode plus ablation catheter for vhpsd q-mode ablation catheter for vhpsd thermocool smarttouch sf catheter for pcrf thermocool cryo other biosense webster devices that were also used in this study: n/a non-biosense webster devices that were also used in this study: n/a adverse event(s) and provided interventions: 1 cardiac tamponade in the q-mode group- no treatment specified 2 pericardial effusions in thermocool smarttouch group- no treatment specified 2 tias in the cyo group- no treatment specified.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
UNK_SMART TOUCH UNIDIRECTIONAL SF
Type of Device
CARDIAC ABLATION PERCUTANEOUS CATHETER
Manufacturer (Section D)
BIOSENSE WEBSTER INC
31 technology drive, suite 200
irvine CA 92618
Manufacturer (Section G)
BIOSENSE WEBSTER INC (JUAREZ)
circuito interior norte
1820parque industrial salvacar
juarez 32599
MX   32599
Manufacturer Contact
gabriel alfageme
31 technology drive
irvine, CA 92618
949789-868
MDR Report Key12389421
MDR Text Key268897960
Report Number2029046-2021-01441
Device Sequence Number1
Product Code LPB
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 08/29/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Catalogue NumberUNK_SMART TOUCH UNIDIRECTIONAL
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/29/2021
Initial Date FDA Received08/30/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-